posted
Nuvilex, Inc., through its subsidiaries, engages in the research, development, and marketing of nutraceutical products in the United States and internationally. The company has researched and developed a range of whole foods and nutraceutical products to help improve various health conditions, including glucose metabolism, scarring, acne, cholesterol, common cold, influenza, and other known pathogens, such as staphylococcus and streptococcus. Its lead product includes Cinnergen, a liquid whole food nutritional supplement that regulates blood sugar levels in Type II diabetics. The company also develops additional products that are in the development and/or clinical trials stages that consist of Citroxin, which is being tested on chicken embryos for bird flu in Thailand, as well as to eradicate the MRSA strain of staph in vitro. In addition, it distributes a topical cream, known as Talsyn-CI/bid Scar Cream, which is used for the management of keloids, hypertrophic scars, erythema multiforme, and surgical incisions. Further, the company develops the Immune Boost Bar designed to enhance overall immune function and help increase resistance to common viruses; and PurEffect, a 4-step anti-acne skin care treatment system designed to address the needs of people suffering from acne. Additionally, it develops Cinnechol, a nutritional supplement designed to naturally promote healthy cholesterol and triglyceride levels, as well as enhance overall cardiovascular health. The company was formerly known as eFoodSafety.com, Inc. and changed its name to Nuvilex, Inc. on March 18, 2009. Nuvilex is based in Cherry Hill, New Jersey.
posted
Nuvilex, Inc. Announces that Legacy Biotechnologies' Reme-Flu with Syn-X9 Formulation Receives FDA National Drug Code Number. Legacy Biotechnologies is now Preparing for Reme-Flu™ Market Launch
.Companies:Nuvilex, Inc..Press Release Source: Nuvilex, Inc. On Tuesday February 2, 2010, 4:15 pm EST CHERRY HILL, N.J.--(BUSINESS WIRE)--Nuvilex, Inc. (OTC Bulletin Board: NVLX - News), announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has received its National Drug Code numbers (50107-100-00, 50107-200-00, and 50107-300-00), from the Food and Drug Administration (FDA) for its homeopathic flu remedy. A National Drug Code (NDC) is a universal identifier of any product that is to be marketed as a drug for human use within the United States. The Drug Listing Act of 1972 states that all registered drug establishments must provide to the FDA a current list of all drugs manufactured, prepared, propagated, compounded, or processed by the establishment for commercial distribution.
As a registered homeopathic medicine, Reme-Flu™ is intended for use at the onset of flu or flu-like symptoms and contains ingredients widely recognized to reduce and/or shorten flu or flu-like symptoms. Legacy Biotechnologies’ Syn-X9™ formulation enhances the body’s utilization of Reme-Flu's™ active ingredients.
With the issuance of the NDC for Reme-Flu™, Legacy Biotechnologies is now preparing to manufacture, market and sell Reme-Flu™ for the spring 2010 flu season. Further details on Legacy’s marketing plans will be forthcoming.
“Legacy Biotechnologies has undertaken the appropriate and necessary steps to register Reme-Flu™ with the FDA insuring that Reme-Flu™, its labeling and packaging meet FDA standards for homeopathic remedies,” stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc. “The registration process for Reme-Flu™ was exacting and time consuming, but was necessary in order to ensure that Reme-Flu™ could legally enter the marketplace. We greatly appreciate Legacy Biotechnologies’ building, registering and launching Reme-Flu™ with a commitment to quality, performance and customer satisfaction.”
According to the FDA Code of Federal Regulations, registration of a drug establishment or drug wholesaler, or assignments of a registration number, or assignment of an NDC number, does not in any way denote approval of the firm or its products.
Posts: 149 | Registered: Oct 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
